Overview: NICE Endorses AUCATZYL for Expanded Use The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL® (obecabtagene autoleucel) for a broader patient population in the United Kingdom. This decision follows a rigorous review of clinical data, cost-effectiveness, and real-world impact on NHS services. AUCATZYL is a next-generation CAR-T therapy designed to harness…